Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well ...

and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from its Phase 2a clinical ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, ...

and glucagon receptor (GCGR). While the clinical results are promising, InvestingPro analysis shows the company is quickly burning through cash, with negative EBITDA of $28.79 million in the last ...

Structure Therapeutics Inc.’s GPCR share price has surged by 29.14%, which has investors questioning if this is right time to sell.

Its core upcoming pipeline is Mazdutide, a GLP-1R/GCGR dual agonist for obesity and type 2 diabetes (T2D). GLP-1R is the receptor for the glucagon-like peptide 1 (GLP-1) hormone which is critical ...

MetaVia Inc. ( Nasdaq: MTVA) announced that a late-breaking abstract highlighting Phase 2a data from its DA-1241 program in presumed metabolic dysfunction-associated steatohepatitis (MASH) has been ...

Devices Inc. , a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial ...

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today ...